Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

Fig. 1

The efficacy of immune checkpoint inhibitors in patients with head and neck cancer. a The best percentage change from baseline in target lesion size was assessed for patients with at least one follow-up scan of the target lesions (n = 38). b Treatment exposure and response duration for patients with at least stable disease as per RECIST v1.1 (n = 20). HNSCC head and neck squamous cell carcinoma, NPC nasopharyngeal cancer, CPS combined positive score, NA not available, CR complete response, PR partial response, SD stable disease, PD progressive disease

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us